175 related articles for article (PubMed ID: 30527181)
1. Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
Anai S; Iwama E; Yoneshima Y; Otsubo K; Tanaka K; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Dec; 126():156-161. PubMed ID: 30527181
[TBL] [Abstract][Full Text] [Related]
2. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
Bandyopadhyay A; Sharma S; Behera D; Singh N
Oncologist; 2021 Aug; 26(8):701-713. PubMed ID: 33728696
[TBL] [Abstract][Full Text] [Related]
3. Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.
Negoro Y; Yano R; Yoshimura M; Suehiro Y; Yamashita S; Kodawara T; Watanabe K; Tsukamoto H; Nakamura T; Kadowaki M; Morikawa M; Umeda Y; Anzai M; Ishizuka T; Goto N
Int J Clin Oncol; 2019 Mar; 24(3):256-261. PubMed ID: 30328531
[TBL] [Abstract][Full Text] [Related]
4. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
[No Abstract] [Full Text] [Related]
5. Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
Sharma P; Singh N; Sharma S
J Biochem Mol Toxicol; 2023 Mar; 37(3):e23269. PubMed ID: 36507589
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR
J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543
[TBL] [Abstract][Full Text] [Related]
7. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
[TBL] [Abstract][Full Text] [Related]
8. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
[TBL] [Abstract][Full Text] [Related]
9. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Font A; Sánchez JM; Tarón M; Martinez-Balibrea E; Sánchez JJ; Manzano JL; Margelí M; Richardet M; Barnadas A; Abad A; Rosell R
Invest New Drugs; 2003 Nov; 21(4):435-43. PubMed ID: 14586211
[TBL] [Abstract][Full Text] [Related]
10. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
[No Abstract] [Full Text] [Related]
11. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.
Kitagawa C; Ando M; Ando Y; Sekido Y; Wakai K; Imaizumi K; Shimokata K; Hasegawa Y
Pharmacogenet Genomics; 2005 Jan; 15(1):35-41. PubMed ID: 15864124
[TBL] [Abstract][Full Text] [Related]
15. Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
Sallam M; Wong H; Escriu C
BMC Pulm Med; 2019 Nov; 19(1):195. PubMed ID: 31675940
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
Balasubramaniam S; Redon CE; Peer CJ; Bryla C; Lee MJ; Trepel JB; Tomita Y; Rajan A; Giaccone G; Bonner WM; Figg WD; Fojo T; Piekarz RL; Bates SE
Anticancer Drugs; 2018 Jun; 29(5):457-465. PubMed ID: 29420340
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms in the
Walia HK; Singh N; Sharma S
Future Oncol; 2021 Dec; 17(35):4925-4946. PubMed ID: 34672683
[TBL] [Abstract][Full Text] [Related]
18. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
[TBL] [Abstract][Full Text] [Related]
19. Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum.
Takano M; Yamamoto K; Tabata T; Minegishi Y; Yokoyama T; Hirata E; Ikeda T; Shimada M; Yamada K; Morita S; Ando Y; Hirata K; Sugihara M; Sugiyama T; Ohashi Y; Sakata Y
Asia Pac J Clin Oncol; 2016 Jun; 12(2):115-24. PubMed ID: 26862009
[TBL] [Abstract][Full Text] [Related]
20. UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
Yamasaki S; Tanimoto K; Kohno K; Kadowaki M; Takase K; Kondo S; Kubota A; Takeshita M; Okamura S
Ann Hematol; 2015 Jan; 94(1):65-9. PubMed ID: 25055799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
